A pharmaceutical solutions provider needed the payment landscape, likely pricing under CMED evaluation, and reimbursement barriers for treatment options across Parkinson's disease, ADHD, schizophrenia, and knee osteoarthritis in Brazil.
We ran in-depth interviews of 60 minutes with Brazilian payers — the people inside the reimbursement decision — covering unmet needs from the payer perspective, expectations of new entrants, likely price positioning, and the pathway to private-insurance coverage.
Analyzed results delivered in under two weeks.
Market access questions answered by the market's actual gatekeepers. Talk to our team.